Telemus Capital LLC reduced its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 43.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,041 shares of the biopharmaceutical company’s stock after selling 3,909 shares during the quarter. Telemus Capital LLC owned approximately 308.00% of Bristol-Myers Squibb worth $321,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of BMY. Tradewinds Capital Management LLC grew its stake in shares of Bristol-Myers Squibb by 34.6% in the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 500 shares in the last quarter. Atlantic Trust LLC bought a new position in shares of Bristol-Myers Squibb in the second quarter valued at $111,000. American National Bank grew its stake in shares of Bristol-Myers Squibb by 11.7% in the second quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 225 shares in the last quarter. Blue Chip Partners Inc. grew its stake in shares of Bristol-Myers Squibb by 0.7% in the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares in the last quarter. Finally, BDO Wealth Advisors LLC bought a new position in Bristol-Myers Squibb during the second quarter worth $123,000. 69.80% of the stock is owned by institutional investors.
Bristol-Myers Squibb Co (NYSE BMY) traded up $0.20 during mid-day trading on Thursday, reaching $62.80. The company had a trading volume of 7,132,976 shares, compared to its average volume of 6,390,000. The firm has a market capitalization of $102,780.00, a P/E ratio of 24.72, a PEG ratio of 2.21 and a beta of 1.18. Bristol-Myers Squibb Co has a fifty-two week low of $48.32 and a fifty-two week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59.
The business also recently declared a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.55%. The ex-dividend date is Thursday, January 4th. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s payout ratio is 62.99%.
BMY has been the subject of a number of research analyst reports. UBS Group reaffirmed a “buy” rating and set a $72.00 price objective (up from $62.00) on shares of Bristol-Myers Squibb in a research report on Friday, October 6th. Vetr raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price objective for the company in a research report on Monday, October 9th. Zacks Investment Research cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Citigroup lifted their price objective on shares of Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Finally, BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Thursday, October 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $65.38.
In related news, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the transaction, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Theodore R. Samuels II bought 4,000 shares of the stock in a transaction on Friday, December 15th. The shares were acquired at an average cost of $62.30 per share, with a total value of $249,200.00. Following the purchase, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.
WARNING: This report was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/02/01/telemus-capital-llc-has-321000-holdings-in-bristol-myers-squibb-co-bmy.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.